Chief Medical Officer and Chairman of the Advisory Board
Dr. Sackier joined the Company in December of 2014 as Chief Medical Officer and brings to his role extensive experience in new technologies and treatment methodologies gained over more than 30 years in the healthcare industry. He is widely recognized as one of the leaders of the laparoscopic surgery revolution. A trained surgeon, Jonathan Sackier has collaborated with pharmaceutical and medical device technology partners including ConvaTec, Pfizer, Karl Storz, Applied Medical, Stryker, Siemens, Bayer and Novartis. He helped build several companies including medical technology, research and product-design and medical contract sales organizations. In addition to his role as CMO, Dr. Sackier has been a Visiting Professor of Surgery at the Nuffield Department of Surgical Sciences at Oxford University since 2014. From 2005 to 2014, Dr. Sackier was a Visiting Professor of Surgery at University of Virginia and prior to that a Clinical Professor at George Washington University in Washington, DC. from 1995 to 1999 when he ceased clinical affiliation but retained his academic affiliation. Dr. Sackier founded and funded the Washington Institute of Surgical Endoscopy, a center for education, research, innovation and technology transfer in 1995. Prior, he worked to develop and market the AESOP robot with Computer Motion from 1992 to 1998 when that company went through a successful IPO in 1997.
Dr. Sackier currently sits on the board of directors of Kypha (since 2014 and was Chairman of that board from 2014-2016), Clinvue (since 2010), and Brandon Medical (since 2009), is a Trustee of First Star and previously chaired The Larry King Cardiac Foundation Board of Governors. Dr. Sackier was also Director for Hemoshear from 2008 to 2015 and served as Chairman of Adenosine Therapeutics which became part of Clinical Data and then Forest Laboratories from 2002 to 2008. He has also served as a board member of The American College of Surgeons Foundation, The Surgical Fellowship Foundation and Rex Bionics, winner of London’s 2014 Aim Award for outstanding achievement for most successful growth market.